Literature DB >> 18591254

MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators.

Galina Gabriely1, Thomas Wurdinger, Santosh Kesari, Christine C Esau, Julja Burchard, Peter S Linsley, Anna M Krichevsky.   

Abstract

Substantial data indicate that microRNA 21 (miR-21) is significantly elevated in glioblastoma (GBM) and in many other tumors of various origins. This microRNA has been implicated in various aspects of carcinogenesis, including cellular proliferation, apoptosis, and migration. We demonstrate that miR-21 regulates multiple genes associated with glioma cell apoptosis, migration, and invasiveness, including the RECK and TIMP3 genes, which are suppressors of malignancy and inhibitors of matrix metalloproteinases (MMPs). Specific inhibition of miR-21 with antisense oligonucleotides leads to elevated levels of RECK and TIMP3 and therefore reduces MMP activities in vitro and in a human model of gliomas in nude mice. Moreover, downregulation of miR-21 in glioma cells leads to decreases of their migratory and invasion abilities. Our data suggest that miR-21 contributes to glioma malignancy by downregulation of MMP inhibitors, which leads to activation of MMPs, thus promoting invasiveness of cancer cells. Our results also indicate that inhibition of a single oncomir, like miR-21, with specific antisense molecules can provide a novel therapeutic approach for "physiological" modulation of multiple proteins whose expression is deregulated in cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591254      PMCID: PMC2519720          DOI: 10.1128/MCB.00479-08

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  60 in total

1.  A microarray study to characterize the molecular mechanism of TIMP-3-mediated tumor rejection.

Authors:  Paula Lam; Kar Sian Lim; Suk Mei Wang; Kam M Hui
Journal:  Mol Ther       Date:  2005-07       Impact factor: 11.454

2.  Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.

Authors:  Matthias Kotzsch; Juliane Farthmann; Axel Meye; Susanne Fuessel; Gustavo Baretton; Vivianne C G Tjan-Heijnen; Manfred Schmitt; Thomas Luther; Fred C G J Sweep; Viktor Magdolen; Paul N Span
Journal:  Eur J Cancer       Date:  2005-10-26       Impact factor: 9.162

3.  Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.

Authors:  Martine L M Lamfers; Davide Gianni; Ching-Hsuan Tung; Sander Idema; Frederik H E Schagen; Jan E Carette; Paul H A Quax; Victor W Van Beusechem; W Peter Vandertop; Clemens M F Dirven; E Antonio Chiocca; Winald R Gerritsen
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

4.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

5.  Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer.

Authors:  Dennis Löffler; Katja Brocke-Heidrich; Gabriele Pfeifer; Claudia Stocsits; Jörg Hackermüller; Antje K Kretzschmar; Renate Burger; Martin Gramatzki; Conny Blumert; Kay Bauer; Helena Cvijic; A Kerstin Ullmann; Peter F Stadler; Friedemann Horn
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

Review 6.  Role of osteoprotegerin (OPG) in cancer.

Authors:  Ingunn Holen; Claire M Shipman
Journal:  Clin Sci (Lond)       Date:  2006-03       Impact factor: 6.124

Review 7.  Oncomirs - microRNAs with a role in cancer.

Authors:  Aurora Esquela-Kerscher; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

8.  miRBase: microRNA sequences, targets and gene nomenclature.

Authors:  Sam Griffiths-Jones; Russell J Grocock; Stijn van Dongen; Alex Bateman; Anton J Enright
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

9.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

10.  Individual Timp deficiencies differentially impact pro-MMP-2 activation.

Authors:  Jane L English; Zamaneh Kassiri; Ilpo Koskivirta; Susan J Atkinson; Marco Di Grappa; Paul D Soloway; Hideaki Nagase; Eero Vuorio; Gillian Murphy; Rama Khokha
Journal:  J Biol Chem       Date:  2006-02-09       Impact factor: 5.157

View more
  370 in total

1.  miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival.

Authors:  An Hu; Jing-Juan Huang; Wei-Hua Xu; Xiao-Jie Jin; Ji-Ping Li; Yuan-Jia Tang; Xin-Fang Huang; Hui-Juan Cui; Guang-Bin Sun
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.

Authors:  Arti B Gaur; Susan L Holbeck; Nancy H Colburn; Mark A Israel
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

3.  MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells.

Authors:  Yingjie Yu; Shailender S Kanwar; Bhaumik B Patel; Phil-Sun Oh; Jyoti Nautiyal; Fazlul H Sarkar; Adhip P N Majumdar
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

4.  Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma.

Authors:  Alexander Baraniskin; Jan Kuhnhenn; Uwe Schlegel; Abdelouahid Maghnouj; Hannah Zöllner; Wolf Schmiegel; Stephan Hahn; Roland Schroers
Journal:  Neuro Oncol       Date:  2011-09-21       Impact factor: 12.300

Review 5.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

6.  miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1.

Authors:  Mian Ling Chen; Liu Sen Liang; Xiao Kang Wang
Journal:  Clin Exp Metastasis       Date:  2012-03-10       Impact factor: 5.150

7.  The metalloproteinase inhibitor Reck is essential for zebrafish DRG development.

Authors:  Andrew Prendergast; Tor H Linbo; Tanya Swarts; Josette M Ungos; Hillary F McGraw; Shlomo Krispin; Brant M Weinstein; David W Raible
Journal:  Development       Date:  2012-02-01       Impact factor: 6.868

Review 8.  Long noncoding RNAs: a new regulatory code in osteoarthritis.

Authors:  Xiao Cen; Xin-Qi Huang; Wen-Tian Sun; Qing Liu; Jun Liu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 9.  The microRNA networks of TGFβ signaling in cancer.

Authors:  V P Sivadas; S Kannan
Journal:  Tumour Biol       Date:  2013-12-10

Review 10.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.